Lunesta DTC ads most recalled by TV viewers

Share this article:
DTC TV ads for Sepracor’s sleep aid Lunesta were the “most recalled” by consumers, according to new data from the advertising effectiveness rating firm IAG Research. Lunesta’s performance was also significant when compared to all other TV commercials, across all product categories, an IAG Research study conducted between September 2005 and September 2006 found. The “luna moth” that appears in the Lunesta spots, created by McCann-Erickson HumanCare, is recognized by adult viewers at a rate more than twice the average for all other new prescription drug ads, IAG Research said. Ads for Novartis’ irritable bowl syndrome treatment Zelnorm, from Deutsche and spots for Schering-Plough’s Nasonex, created by BBDO New York, also resonated with consumers, the study found. IAG Research’s pharmaceutical practice VP Fariba Zamaniyan said in a statement that “The above-average performances achieved by these brands confirm that direct-to-consumer advertising for prescription drugs can achieve breakthrough and brand recognition, even within the rigid guidelines this category faces.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...